$TMXN.012 - Trump-MMJ-NEWS POT-STOCKS MASSIVE-REVERSAL-STARTS $CERN $HSIC $PG $MRK $MYL $VRX $VRTX $BIIB $BMY $JNJ… https://t.co/M8bIho7sf3
RT @JohnCendpts: #AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda
$MRK $BMY
https://t.…
Forgot tickers, looking forward to this, should be a big plenary tomorrow #AACR18 $BMY $AZN $MRK https://t.co/gPlPvVfLZS
RT @IBD_ECarson: Futures jump after Syria 'mission accomplished'; Watch these 5 stocks Monday https://t.co/1gHPHVKNqo $NFLX $MRK $BAC $SCHW…
Futures jump after Syria 'mission accomplished'; Watch these 5 stocks Monday https://t.co/1gHPHVKNqo $NFLX $MRK… https://t.co/BSVbs9ItZx
RT @tgtxdough: BMO sharp analyst Alex Arfaei out with Rationale for Our KN-189 Predictions and Scenario Analysis $MRK $BMY @AndyBiotech @b…
RT @matthewherper: Tim Anderson at Bernstein predicting Monday's #AACR18 data will be seen as a $MRK win over $BMY. Expectations high.
RT @JacobPlieth: Weekend reading: 6 questions ahead of Monday's #AACR18 1L lung cancer showdown between $MRK $BMY & $RHHBY. Via @EPVantage…
$AZN $36.29 -0.030 (0.083%) $MRK $ 57.35 +0.18 (0.31%) - News Out
https://t.co/jMcHQLO44V
RT @princetongb: SD-101 + Pembro in Melanoma - #AACR18 result: Median PFS, duration of response and OS have not been reached. Estimated 12…
Could it be another possible buyout Monday?
Could $SAGE $BIIB tie the knot after the late conference cancellation… https://t.co/7V3Umg0uT0
RT @PDRennert: The trial design here is brilliant. Adjuvant treatment with #pembrolizumab instage 3 #melanoma Kudos $MRK and Dr Eggermont.…
RT @PDRennert: The trial design here is brilliant. Adjuvant treatment with #pembrolizumab instage 3 #melanoma Kudos $MRK and Dr Eggermont.…
RT @fwpharma: Merck & Co. details positive late-stage data for Keytruda in adjuvant melanoma https://t.co/T0R0HSOCfu $MRK #AACR18
RT @cavallimedia1: Extremely bullish article in SA published late Friday says and explains in detail why $AMPE buyout at $6+ billion is IMM…
$AZN, $MRK Reveal findings from late-stage study evaluating LYNPARZA in metastatic breast cancer patients https://t.co/gYLcsgZ5bg
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update https://t.co/hg3CNxxgeF #investing #SundayFun…
@FiercePharma Most important thing to look for in KN-189: how did the combo do in PDL1 low expresser subgroup. BMY’… https://t.co/rOPHaoHBhj
RT @VistaPResearch: #BreastCancer Therapy Innovator Atossa Genetics Announces Progress in Phase 1 study of Topical Endoxifen in Men https:/…
$MRK $57.35 +0.18 (0.31%) - News Out on Merck
https://t.co/eTI7LQ5CgP
RT @thejadedtrader: $SYBX related Andreas Jurgeit, Investment Director of the Life Science team of $MRK Ventures remarks that the companies…
RT @fezziwig2008: $AZN $MRK $NVO
https://t.co/7YFtT4Wapr
RT @permabear_uk: United Health $UNH is one of the strongest stocks out there, and has earnings Tues' morning. FPE 15s. NM 5.2%. $C are no…
$AZN $MRK $NVO
https://t.co/7YFtT4Wapr
$NSPX HUGE Merger! NO PR #BIOTECH
https://t.co/O636BZkzuz
$RDUS $UTHR $PTLA $ALDR $OPK $GLPG $ARWR $ONCS $MTEM… https://t.co/TGdIIpmZVg
Venture Capital Deals Of The Week: Tencent Led $3B Investment
Apr. 14, 2018 10:44 AM ET
$TCEHY $TCTZF $BABA $MRK… https://t.co/qTJRyliuD4
$NSPX HUGE Merger! NO PR #PHARMA
https://t.co/O636BZkzuz
$RDUS $UTHR $PTLA $ALDR $OPK $GLPG $ARWR $ONCS $MTEM $SGYP… https://t.co/dAzBbayqQ6
RT @PDRennert: The trial design here is brilliant. Adjuvant treatment with #pembrolizumab instage 3 #melanoma Kudos $MRK and Dr Eggermont.…
RT @drug_czar: With a week left to go, here's a preview of the Immunotherapy-combo showdown at #AACR18 where Keytruda, Opdivo, and Tecentri…
United Health $UNH is one of the strongest stocks out there, and has earnings Tues' morning. FPE 15s. NM 5.2%. $C… https://t.co/0W22ip6pUk
2018-04-13 Short volume percent for $EXEL is 33%. https://t.co/RqbJAJ1mTc $PFE 65% $JNJ 31% $MRK 48% $SNY 33%
$MRK MAY 60C big action on Friday, may have data Monday, but name to watch here:
https://t.co/CvTCzl9F4V
Commented on $JNJ $MRK $PFE $SNY $AMPE https://t.co/B4IJLu1Us0
RT @odibro: $AZN $MRK Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presen…
$MYL $MRK https://t.co/7vFFA93jlh
RT @Merck: Sharing updated #BreastCancer data presented at #AACR18 today with @AstraZenecaUS: https://t.co/TQgSLgeNFX $MRK
RT @odibro: $AZN $MRK Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presen…
$NSPX HUGE Merger! NO PR #PHARMA
https://t.co/O636BZkzuz
$RDUS $UTHR $PTLA $ALDR $OPK $GLPG $ARWR $ONCS $MTEM $SGYP… https://t.co/G6oZQsqLk8
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18 https://t.co/hg3CNxxgeF #investing #…
RT @odibro: $AZN $MRK Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presen…
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18 https://t.co/hg3CNxxgeF #investing #…
RT @Merck: Sharing updated #BreastCancer data presented at #AACR18 today with @AstraZenecaUS: https://t.co/TQgSLgeNFX $MRK
RT @MeTooPropecia: BREAKING: #Merck to pay settlement of as much as $4.29 million to men who have developed cancer, genital disfigurement,…
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18 https://t.co/hg3CNxxgeF #investing #…
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update 4-14-18 https://t.co/hg3CNxxgeF #investing #…
RT @MeTooPropecia: BREAKING: #Merck to pay settlement of as much as $4.29 million to men who have developed cancer, genital disfigurement,…
$NSPX 019?! CANCER PATENT GRANTED NO PR? UNKNOWN 52wkH 55 CENTS
$AAPL $GOOG $INTC $AMZN $MSFT $AKAM $CMCSA $PFE $MU… https://t.co/bmzCEoHHSb
RT @odibro: $AZN $MRK Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presen…
RT @Merck: Sharing updated #BreastCancer data presented at #AACR18 today with @AstraZenecaUS: https://t.co/TQgSLgeNFX $MRK
RT @odibro: $AZN $MRK Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presen…
$AZN $MRK At the final OS data cut-off (64% maturity), nearly 13% of patients remained on LYNPARZA and no patients remained on chemotherapy.
$AZN $MRK While the trial was not powered to demonstrate a statistically-significant difference, the median OS was… https://t.co/g4dGQCsdFf
RT @tgtxdough: BMO sharp analyst Alex Arfaei out with Rationale for Our KN-189 Predictions and Scenario Analysis $MRK $BMY @AndyBiotech @b…
RT @datamonitor_JA: Could it be another possible buyout Monday?
Could $SAGE $BIIB tie the knot after the late conference cancellation last…
RT @BobbyLandman121: Forgot tickers, looking forward to this, should be a big plenary tomorrow #AACR18 $BMY $AZN $MRK https://t.co/gPlPvVfL…
4-star analyst Alex Arfaei from BMO Capital maintained a Buy on $MRK. https://t.co/mow79Pvs4N
RT @VistaPResearch: #BreastCancer Therapy Innovator Atossa Genetics Announces Progress in Phase 1 study of Topical Endoxifen in Men https:/…
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update https://t.co/hg3CNxxgeF #investing #SundayFun…
BMO Capital Sticks to Their Buy Rating for Merck & Company $MRK https://t.co/vhcbfIwihf
$MRK admits to deceptive practices, breach of express & implied warranty. Settles with victims of hair loss drug Pr… https://t.co/Ru5Ri187UH
Merck & Co. $MRK Expected to Post Q1 2018 Earnings of $0.99 Per Share https://t.co/SJulX5wRtJ
Merck & Co. $MRK Expected to Post Q1 2018 Earnings of $0.99 Per Share https://t.co/QBzB6qmJI2 #stocks
Jefferies Group Sets Merck & Co. Q1 2018 Earnings Estimates at $0.99 EPS. https://t.co/FZ1T2rdSev $MRK #MRK
Merck & Co. $MRK Expected to Post Q1 2018 Earnings of $0.99 Per Share https://t.co/GhjIO0RCWy
RT @cavallimedia1: Will speculation in recent article projecting imminent $AMPE $6 Billion buyout by Big Pharma spark a short squeeze?
htt…
RT @andreascseh: Western Jihadists trained in Berlin against Iran #IRGC #Hezbollah #Aleppo... Powered by Made in Germany $MRK All Time High…
Western Jihadists trained in Berlin against Iran #IRGC #Hezbollah #Aleppo... Powered by Made in Germany $MRK All Ti… https://t.co/ZiRYAr5V1a
RT @BursatilBiotech: #AACR18 Ongoing TRK, RET , PD1, ROS1, PD-L1 trials
$NKTR $LOXO $RHHBY $MRK $LLY https://t.co/yOz4xvr0W0
Btw, Estimated #Earnings Per Share for $MRK is $0.96 it's 1.68% of the current price https://t.co/W8qdendJYD
RT @VistaPResearch: Read "Positively Doubting Judgement?” Vista Partners Weekly Market Update https://t.co/hg3CNxxgeF #investing #SundayFun…
@NordnetNO har mange gode innlegg om utbytte denne måneden og jeg har kikket på 3 #utbytteaksjer i… https://t.co/p0z3A4sbhH
Merck & Co.'s buy rating reiterated at BMO Capital Markets. $65.00 PT. https://t.co/A4gdWEW5SD $MRK #MRK
RT @andreascseh: Western Jihadists trained in Berlin against Iran #IRGC #Hezbollah #Aleppo... Powered by Made in Germany $MRK All Time High…
$TCEHY $TCTZF $BABA $MRK $MSFT $RHHBF $RHHBY $NONOF $NVO $CTRP $NVS $VRTX $LPSN $CRM https://t.co/r1bWG8SpAA
$MRK $INCY $ONCS https://t.co/j4z4hiX9ry
RT @BursatilBiotech: #AACR18 Ongoing TRK, RET , PD1, ROS1, PD-L1 trials
$NKTR $LOXO $RHHBY $MRK $LLY https://t.co/yOz4xvr0W0
RT @RecallPropecia: $MRK admits to deceptive practices, breach of express & implied warranty. Settles with victims of hair loss drug Propec…
$MRK Company reports Keytruda reduced the risk of disease recurrence or death by more than 40% compared to placebo… https://t.co/AKAbXU9J8P
$MRK Merck & AstraZeneca present data from the Phase 3 OlympiAD trial showing the final overall survival results f… https://t.co/TLj8LH4lm3
Data from the weekend $AZN $MRK #AACR18
LYMPARZA in pts w/gBRCAm HER2-negative MBC
mOS:
19.3m LYNPARZA vs 17.1m in… https://t.co/XKWE0ed8Gb
RT @larsmkn: @NordnetNO har mange gode innlegg om utbytte denne måneden og jeg har kikket på 3 #utbytteaksjer i #legemiddelbransjen. Ta en…
Gooooooooooooooooooooooooooood Morning, Deareeeeest Biotwitter!
Toooooooooday is D-Day!
1 disease, 3 COs, 3 trials… https://t.co/OzKjkaBWPK
Merck & Co.'s buy rating reiterated at BMO Capital Markets. $65.00 PT. https://t.co/PA78TiX5yw $MRK #MRK
RT @RecallPropecia: $MRK admits to deceptive practices, breach of express & implied warranty. Settles with victims of hair loss drug Propec…
RT @Merck: Sharing updated #BreastCancer data presented at #AACR18 today with @AstraZenecaUS: https://t.co/TQgSLgeNFX $MRK
$MRK Most of the buying on Friday did not stick to Open Interest FYI
$MRK:
Merck’s Keytruda shows treatment benefit in late-stage study in …:
https://t.co/sPnDmX2q3h
Merck's Keytruda shows treatment benefit in late-stage study in advanced melanoma; shares up 1% p... https://t.co/naUWkY9n0j #premarket $MRK
Merck's Keytruda shows treatment benefit in late-stage study in advanced melanoma; shares up 1% p... https://t.co/qdcIn71nru #premarket $MRK
RT @BursatilBiotech: Gooooooooooooooooooooooooooood Morning, Deareeeeest Biotwitter!
Toooooooooday is D-Day!
1 disease, 3 COs, 3 trials
$B…
$MRK HAS EVENT TODAY ANALYST DAY
RT @drug_czar: With a week left to go, here's a preview of the Immunotherapy-combo showdown at #AACR18 where Keytruda, Opdivo, and Tecentri…
RT @nycdoc29: @BursatilBiotech #Opdivo v #Keytruda v #Tecentriq - the use in the real world is far more than who wins data contest today #A…
RT @Merck: Excited to share new data in #melanoma at #AACR18 today: https://t.co/AxJi1LRYVl $MRK
OZ government recently announced subsidizing #Keytruda, for a rare treatment of adults with refractory or relapsed… https://t.co/NTpNm7FQGA
@BursatilBiotech #Opdivo v #Keytruda v #Tecentriq - the use in the real world is far more than who wins data contes… https://t.co/SXbYicpK8h
Johnson & Johnson\'s 1Q18 Earnings: What to Expect on April 17 $JNJ $XLV $BMY $MRK $PFE https://t.co/evwD1yvLnE https://t.co/YufCARXr5o
April 16 Biotech Update $BMY $bpmc $LOXO $MRK $shpg https://t.co/8bpWmgRvil
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Benzin $ARQL $BMY $RIGL $DVAX $TOCA $IBB $MRK $CYCC $GWPH… https://t.co/No4jw3AuOC
$MRK +0.24%
$BMY +0.60%
$RHHBY Unchanged https://t.co/9CAaLWlaOO
$BMY $MRK $DVAX https://t.co/ai7s6jE0bj
RT @AmyDaniel212: #Never stop #believing in #yourself. https://t.co/vT9HmoiNbp #ChangeTheWorld #YouCanDoIt $cvx $mrk $cmcsa $txn $wmt #Frid…
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
$JPM shines with it's annual health conference and knowledge of #biotech
$GS makes blatant mistakes in ratings fo… https://t.co/ZjMmHB4JkA
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
RT @BursatilBiotech: #AACR18 Ongoing TRK, RET , PD1, ROS1, PD-L1 trials
$NKTR $LOXO $RHHBY $MRK $LLY https://t.co/yOz4xvr0W0
RT @AndyBiotech: #Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY CM-227…
#Biotech Busy week ahead!
$RARE PDUFA
$RIGL PDUFA
$GWPH AdCom
$INCY $LLY AdCom BD
Earnings
$JNJ
$NVS
#AACR18
$BMY… https://t.co/ruUqlo8PLq
@BursatilBiotech $MRK My chips are on Merck.
$MRK: Merck & AstraZeneca (AZN) present data from the Phase 3 OlympiAD trial showing the final overall survival... https://t.co/D3TcpsyGUP
@megtirrell $ONVO
@Organovo Achieves Key Development Milestones for Its Liver Disease and Intestinal Tissue Models… https://t.co/gHCd6Poqgq
Today is the day! The mother of all sessions, presentations of KEYNOTE-189, CHECKMATE-227, and IMpower150 at… https://t.co/rBnyDKGds3
$DVAX $MRK:
Dynavax SD-101: Right Drug In The Wrong Combo:
https://t.co/by0Z33tMCJ